INTRODUCTION {#s1}
============

Diagnosis of inherited bone marrow failure syndromes is remarkably difficult because of the striking clinical heterogeneity of these rare diseases. Many patients lack a clear physical or laboratory profile to guide expert clinicians toward a specific single-gene test ([@MCS003152KHUC12]). Therapies required in the setting of acute illness may cloud the ability to pursue diagnostic tests at a later time---for example, blood transfusions may suppress abnormal hematopoiesis and alleviate hemolysis in congenital hemolytic anemia. Nevertheless, it is ultimately essential to establish a diagnosis to recommend management and evidence-based counseling for families affected with these uncommon genetic disorders. Therefore, whole-exome sequencing (WES) is increasingly utilized for unbiased clinical diagnostics in individuals whose symptoms are suggestive of a hereditary disease but not sufficiently specific for targeted gene sequencing ([@MCS003152KHUC3]).

When WES reveals variants of unknown significance (VUS), functional evaluation of the resulting protein changes corroborates the diagnostic findings and may offer clinically useful insights into disease pathogenesis. Ultimately, this approach may unravel unexpected therapeutic options for the affected family. Here, we discuss a child affected with a misdiagnosed genetic disorder, in which WES supported by experimental validation of novel genomic variants established the correct diagnosis and inspired major changes to the proband\'s and family\'s clinical management, eliminating the need for chronic red blood cell (RBC) transfusions.

RESULTS {#s2}
=======

A nondysmorphic Caucasian infant female was referred to us for management of suspected DBA based on transfusion-dependent anemia since the age of 2 mo when she presented with a severe anemia (hemoglobin 3.2 g/dl) and absolute reticulocyte count of 98 K/mm^3^, which was inappropriately low for the degree of anemia ([@MCS003152KHUC5]). DBA is a clinically heterogeneous disorder, and consensus diagnostic criteria for "classical" DBA include age of \<1 yr at the time of anemia onset, low reticulocyte count, lack of other significant cytopenias, and decreased erythrocytic precursors without other major abnormalities in the bone marrow. A positive family history and the presence of mutations within known DBA genes are considered major supporting diagnostic criteria in this complex syndrome; congenital anomalies, elevated adenosine deaminase (ADA), and fetal hemoglobin (Hgb F) represent further minor supporting criteria for DBA ([@MCS003152KHUC18]). The patient\'s family history was reported as normal. Her ADA, pyruvate kinase (PK) activity, and fetal hemoglobin (HgbF) were not tested before the first transfusion. Her bone marrow evaluation was nondiagnostic as specimen dilution prevented quantification of erythroid precursors. There was no jaundice concerning for hemolytic anemia. Given the unclear clinical picture, we considered atypical DBA or another inherited disorder of hematopoiesis. As steroids improve erythropoiesis in DBA and render most patients transfusion-independent ([@MCS003152KHUC2]), we pursued a trial of prednisone (2 mg/kg PO daily) and observed an initial hemoglobin increase to 9.4 g/dl followed by a drop to 5.7 g/dl within a month; therefore, we classified the patient as steroid nonresponsive and discontinued her prednisone. Her DBA-focused sequencing panel and copy-number variation microarray were normal.

The patient required monthly RBC transfusions and developed one hemolytic episode associated with viral illness, resulting in pallor, mild hyperbilirubinemia, and, unexpectedly for presumptive diagnosis of DBA, mild reticulocytosis. We decided to pursue whole-exome sequencing (WES) of the child and her parents to determine the potential underlying inherited cause of her clinical course and allow genetic counseling.

WES of the family revealed that the patient is a compound heterozygote for two erythrocytic α-spectrin (*SPTA1*) variants, consistent with hereditary pyropoikilocytosis ([Table 1](#MCS003152KHUTB1){ref-type="table"}). The first truncating *SPTA1* variant inherited from the father (*c.4975C\>T*; p.R1659X) had been reported in hereditary pyropoikilocytosis ([@MCS003152KHUC16]). The second maternally inherited *SPTA1* variant resulted in a novel missense substitution (*c.5029G\>A*; p.G1677R). This variant affects a conserved spectrin domain outside of the spectrin self-association site and is predicted to be deleterious by PROVEAN and PolyPhen-2 algorithms. Neither *SPTA1* genetic variant was observed in approximately 6000 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating these are not common benign variants in these populations. In retrospect, both parents had a history of mild unexplained anemia with occasional peripheral elliptocytes and the father had chronic hyperbilirubinemia suggestive of hemolysis, consistent with a diagnosis of mild hereditary elliptocytosis ([@MCS003152KHUC9]).

###### 

Genomic findings

  Gene      Genomic location             HGVS cDNA      HGVS protein   Zygosity       Parent of origin   Variant interpretation
  --------- ---------------------------- -------------- -------------- -------------- ------------------ ---------------------------------
  *SPTA1*   Chromosome 1, NC_000001.11   c.4975 C\>T    p.R1659X       Heterozygous   Father             Pathogenic
  *SPTA1*   Chromosome 1, NC_000001.11   *c.5029G\>A*   p.G1677R       Heterozygous   Mother             Variant of unknown significance

Review of the patient\'s pretransfusion smear ([Fig. 1](#MCS003152KHUF1){ref-type="fig"}A) combined with scanning electron microscopy ([Fig. 1](#MCS003152KHUF1){ref-type="fig"}B) revealed microspherocytes, anisopoikilocytosis, and budding RBCs, consistent with congenital hemolytic anemia due to α-spectrin deficiency resulting in dysfunctional RBC membrane cytoskeleton. The patient\'s RBC membrane protein electrophoresis showed the presence of β-spectrin, whereas α-spectrin was nearly undetectable ([Fig. 1](#MCS003152KHUF1){ref-type="fig"}C). Ektacytometry, performed 2 mo after transfusion, detected abnormal RBC flexibility ([Fig. 1](#MCS003152KHUF1){ref-type="fig"}D). Elliptocytes and occasional spherocytes were found on both parents' peripheral blood smears, consistent with the diagnosis of hereditary elliptocytosis. Given these genetic findings and ongoing transfusion needs, the child underwent partial laparoscopic splenectomy removing the distal 85% of the spleen, which resulted in transfusion independence for 12 mo (her transfusion threshold was 7 g/dl). However, the patient\'s transfusion dependence recurred with hemoglobin nadir of 5.9 g/dl, correlating with regrowth of her spleen tissue reported on abdominal ultrasound. The patient next underwent full laparoscopic splenectomy. She remains transfusion-independent with normal hemoglobin more than 6 mo postsplenectomy.

![Red blood cell (RBC) membrane protein deficiency identified via whole-exome sequencing. (*A*) Compound heterozygous *SPTA1* mutations identified via whole-exome sequencing in a child with transfusion-dependent anemia. Note anisopokilocytosis, microcytes, and elliptocytes on the peripheral blood smear. Elliptocytes in parents' peripheral smears are consistent with diagnosis of hereditary elliptocytosis. (*Insert*) Location of the new SPTA1 variant within the spectrin fold. Arrow indicates the affected proband. Healthy brother (white square) was not genetically tested. Mother and father are represented by gray circle and square, respectively. Severity of phenotype in the family members is reflected by grayscale gradient. (*B*) Microspherocytes (yellow arrows), elliptocyte (green arrow), and RBC with membrane extrusions (blue arrows) visualized via scanning electron microscopy in peripheral blood of the patient compared to healthy control. (*C*) Decreased α-spectrin protein in the index patient\'s RBCs. (*D*) Decreased RBC deformability in the index patient.](MCS003152Khu_F1){#MCS003152KHUF1}

DISCUSSION {#s3}
==========

Our patient initially received the clinical diagnosis of suspected DBA based on the severe transfusion-dependent anemia with reticulocytopenia starting in infancy. DBA represents a group of genetically distinct ribosomopathies that manifest hematologically as severely impaired erythropoiesis, although it is not clear how genetic impairment of the ribosome selectively arrests RBC production and produces a wide variety of systemic manifestations that vary between patients ([@MCS003152KHUC14]; [@MCS003152KHUC19]). Lack of dysmorphic features did not exclude this possibility as roughly half of DBA patients are free of gross malformations ([@MCS003152KHUC6]). Our patient\'s ADA activity and hemoglobin F (HgbF) were not tested before her first transfusion and referral to our center. Moreover, we initially did not consider an underlying hemolytic anemia as the cause of her transfusion dependency as she was not jaundiced and did not have gross anipoikilocytosis on her posttransfusion peripheral blood smears, likely because her own erythropoiesis was significantly suppressed by monthly transfusions. However, our retrospective review of her previously inaccessible pretransfusion blood smear revealed anisopoikilocytosis that should have raised the concern of an underlying RBC membrane disorder. These diagnostic challenges highlight the importance of early consultation and provision of original blood and marrow specimens to pediatric hematologists with expertise in inherited bone marrow failure syndromes.

Consistent with a structurally and functionally abnormal RBC membrane cytoskeleton, we observed microspherocytes and bizarrely shaped RBCs on patient\'s posttransfusion RBC scanning electron microscopy but not in the blood of healthy controls processed and imaged in the same manner ([Fig. 1](#MCS003152KHUF1){ref-type="fig"}B). Notably, the simplified approach to RBC scanning electron microscopy we have developed for this work produced high-quality RBC images, suggesting the potential utility of this technically easy strategy to examine RBC structure in more detail compared to conventional microscopy. Ektacytometry confirmed abnormal deformability of the patient\'s RBCs resulting from the biochemically validated deficiency of RBC membrane-associated α-spectrin in this child ([Fig. 1](#MCS003152KHUF1){ref-type="fig"}C,D); in fact, it likely underestimated the severity of RBC membrane defect because these experiments were done 2 mo post--RBC transfusion and therefore evaluated a mixture of normal and SPTA1^p.R1659X/p.G1677R^ RBCs. Although this study did not examine the relative contribution of the paternal (p.R1659X) and maternal (p.G1677R) mutation, we hypothesize the paternal mutation is more severe as it truncates the protein and the father had a known mild borderline hemolysis.

Different pathophysiology of DBA and RBC membrane disorders provides distinct therapeutic opportunities. In DBA, anemia is caused by impaired RBC production. Steroids rescue erythropoiesis in \>50% of DBA patients; others require RBC transfusions for their lifetimes or hematopoietic stem cell transplantation ([@MCS003152KHUC17]). Long-term care of these complex patients requires aggressive management of toxic iron overload resulting from chronic transfusions, side effects of chronic steroid use, as well as cancer surveillance. Contrastingly, in hereditary RBC membranopathies, anemia is caused by elimination of misshapen RBCs by spleen macrophages beyond the bone marrow\'s ability to compensate for hemolysis. Therefore, splenectomy provides a viable surgical option to manage severe RBC membrane disorders. However, the potential benefits of decreased transfusion dependency must be balanced with the long-term risk of overwhelming postsplenectomy infections (OPSIs) ([@MCS003152KHUC10]; [@MCS003152KHUC8]) requiring immunizations against encapsulated bacteria as well as prophylactic penicillin ([@MCS003152KHUC7]). Subtotal splenectomy may alleviate transfusion dependency in severe hereditary spherocytosis ([@MCS003152KHUC1]; [@MCS003152KHUC4]) and neonatal pyropoikilocytosis ([@MCS003152KHUC11]) without increasing the risk of OPSIs and thrombosis. Some ([@MCS003152KHUC11]) but not all ([@MCS003152KHUC13]; [@MCS003152KHUC4]) children with hemolytic anemia post--partial splenectomy require full splenectomy at a later time. Therefore, the risks and benefits of splenectomy in children with RBC membrane disorders should be carefully examined on a personalized basis.

In our patient, we decided to initially proceed with partial splenectomy because of the patient\'s young age. Although this approach provided a temporary decrease in transfusion needs, our patient ultimately required a complete splenectomy \>12 mo later as her transfusion-dependent anemia reoccurred, presumably because of increased RBC destruction in the expanding remainder splenic tissue. Total splenectomy eliminated our patient\'s transfusion dependence, halting her transfusion-related iron overload and exposure to blood products, minimizing her need for clinic visits. The diagnosis not only allowed genetic counseling for the family but also provided information relevant to the parents' health maintenance, including their risk of chronic hemolysis and cholelithiasis due to chronic subclinical hemolysis. Interestingly, the child\'s father had been undergoing evaluation for suspected Gilbert\'s syndrome at another facility because of mild asymptomatic hyperbilirubinemia, which we now believe is due to his chronic hemolysis secondary to his SPTA1^R1659X^ truncation.

WES is not free of limitations. First, this diagnostic technique will not identify pathogenic mutations located outside of the exome and may not capture large DNA deletions or duplications ([@MCS003152KHUC12]). Second, identification of VUS may cause unique challenges as detailed functional analysis of VUSs, as reported in this study, is not always possible. However, this case illustrates the clinical utility of WES in children with rare congenital disorders that have unclear clinical presentation and/or laboratory profile ([@MCS003152KHUC15]).

METHODS {#s4}
=======

Whole-Exome Sequencing {#s4a}
----------------------

Patients' and parents' diagnostic whole-exome sequencing of nuclear and mitochondrial DNA was done at GeneDx. Using genomic DNA from the submitted specimen, the Agilent Clinical Research Exome kit was used to target the exonic regions and flanking splice junctions of the genome. These targeted regions were sequenced simultaneously by massively parallel (NextGen) sequencing on an Illumina HiSeq 2000 sequencing system with 100-bp paired-end reads. Bidirectional sequence was assembled, aligned to reference gene sequences based on human genome build GRCh37/UCSC hg19, and analyzed for sequence variants using a custom-developed analysis tool (Xome Analyzer). Capillary sequencing or another appropriate method was used to confirm all potentially pathogenic variants identified in this individual and relative samples. Sequence alterations were reported according to the Human Genome Variation Society (HGVS) nomenclature guidelines. Mean depth of coverage (mean number of sequence reads obtained across the whole exome; specifically, the coding exons and splice junctions of protein-coding RefSeq genes that are captured by the Agilent Clinical Research Exome kit) was 111×. Additionally, the entire mitochondrial genome from each sample was amplified and sequenced using a solid-state sequencing by synthesis process. DNA sequence was assembled and analyzed in comparison with the revised Cambridge Reference Sequence (rCRS) and the reported variants and polymorphisms listed in the MITOMAP database (<http://www.mitomap.org>). The initial DBA next-gen panel (*RPS19*, *RPL5*, *RPS10*, *RPL11*, *RPL35A*, *RPS26*, *RPS24*, *RPS17*, *RPS7*, *RPL19*, and *RPL26*) was done at Ambry Genetics. See [Table 2](#MCS003152KHUTB2){ref-type="table"} for the WES metrics.

###### 

Whole-exome sequencing metrics

  ------------------------------------------------ -------
  Mean depth of coverage                           111×
  Percentage of exome with at least 10× coverage   96.1%
  ------------------------------------------------ -------

RBC Evaluation {#s4b}
--------------

For scanning electron microscopy, blood samples in fixative (2% paraformaldehyde/2% glutaraldehyde in phosphate buffer) were air-dried on silicon wafers overnight. Then gold-palladium sputter coating specimens were viewed and imaged with a JEOL, LV 6390 (Peabody) Scanning Electron Microscope. Peripheral blood smear images were acquired on a Zeiss Axio Lab.A1 microscope with an Axiocam 105 color camera and processed with ZEN (Carl-Zeiss) and Imaris (Bitplane) software. Osmotic gradient ektacytometry was performed and interpreted at the RBC Laboratory, Children\'s Oakland Research Institute, UCSF Benioff\'s Children\'s Hospital, Oakland, CA. Specimen was shipped overnight in room temperature and accompanied by healthy travel control to ensure results are not affected by shipping.

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

The variants were submitted to ClinVar (<http://www.ncbi.nlm.nih.gov/clinvar/>) and can be found under accession numbers SCV000804855.1 and SCV000804576. Patient consent was not obtained for deposition of raw sequencing data.
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